Genmab — Juni 2017
-
bluebird bio logobluebird bio Inc (NASDAQ:BLUE)‘s stock had its “buy” rating restated by research analysts at Jefferies Group LLC in a note issued to investors on Friday. They currently have a $88.00 price objective on the biotechnology company’s stock. Jefferies Group LLC’s price target points to a potential upside of 6.80% from the stock’s current price.
-
Spændende om der kommer en lille positiv markedsreaktion imorgen ovenpå ASCO.
-
Hvis du bruger Nordnet, kan du handle Bull Gen x2 uden kurtage. Ellers er de i bund og grund det samme med omkostninger på ca. 0,5 % pr år. Går udbyderen konkurs er pengene tabt, måske du vil have det med i overvejelserne.
-
-
Fase 1b Isa+pom+dex 75% ORR i R/RMM https://www.youtube.com/watch?v=ipb_ny6muqY&list=PLAWij8qSJy6R9fZC8pK0RBrhRkbghEPgO&index=9
-
Jeg har Bull Genmab *3 fra Commerzbank købt på Nordnet. Det er et certifikat jeg er tilfreds med, og regner med at beholde en rum tid endnu, da jeg fortsat har stor tiltro til Genmab casen.
-
God morgen.
Børsen http://borsen.dk/nyheder/avisen/artikel/11/172036/artikel.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind